Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters
 

Head and Neck Cancer Clinical Trials

A listing of Head and Neck Cancer medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (539) clinical trials

C.A.T.S. Cancer and Tobacco Study Head/Neck Cancer Patients Needed for a Research Study A UK research study aims to better underdtand the changes people experience after head/neck cancer diagnosis (e.g., change in mood, tobacco use, social life). Study participation is voluntary, and answers to study questions are confidential. This is ...

Phase N/A

MGCD516 is a receptor tyrosine kinase (RTK) inhibitor shown in preclinical models to inhibit a closely related spectrum of RTKs including MET, AXL, MER, and members of the VEGFR, PDGFR, DDR2, TRK and Eph families. In this study, MGCD516 is orally administered to patients with advanced solid tumor malignancies to ...

Phase

The relatively restricted C4.4a expression pattern provides a target for the selective delivery of a cytotoxic drug to C4.4.a-expressing tumor cells by means of a suitable antibody-drug conjugate. The subject population eligible for the current study will be those subjects with advanced malignancies known to express C4.4a, which are refractory ...

Phase

For more information please visit: http://clinicaltrials.gov/ct2/show/NCT00956007?term=RTOG+0920&rank=1

Phase

For more information please visit: http://clinicaltrials.gov/ct2/show/record/NCT00588770?term=e1305&rank=1

Phase

The purpose of this study is to determine the safety, tolerability, and efficacy of epacadostat when given in combination with nivolumab and ipilimumab, and in combination with nivolumab and lirilumab, in subjects with advanced or metastatic malignancies.

Phase N/A

This is a clinical trial aimed to determine the best tolerated dosage of Cetuximab into arteries for the treatement of un-resectable recurrent head and neck cancer. Cetuximab belongs in a class of drugs called epidermal growth factor receptor (EGFR) inhibitors. A high percentage of head and neck cancers over-express EGFR. ...

Phase

All enrolled patients will receive CDX-3379 and cetuximab. All patients in the study will be closely monitored to determine if there is a response to the treatment and for any side effects that may occur.

Phase